Llwytho...
Acquired resistance to BRAFi reverses senescence-like phenotype in mutant BRAF melanoma
Targeting MAPK pathway in mutant BRAF melanoma with the specific BRAF inhibitor vemurafenib showed robust initial responses in the majority of patients followed by relapses due to acquired resistance to the drug. In (V600E)BRAF melanoma cell lines, senescence-associated β-galactosidase activity is o...
Wedi'i Gadw mewn:
| Cyhoeddwyd yn: | Oncotarget |
|---|---|
| Prif Awduron: | , , , , , , |
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
Impact Journals LLC
2018
|
| Pynciau: | |
| Mynediad Ar-lein: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6112757/ https://ncbi.nlm.nih.gov/pubmed/30159130 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.25879 |
| Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|